The Emergence of Bispecific T-Cell Engagers in the Treatment of Follicular and Large B-Cell Lymphomas

Abstract: The rapid emergence of CD20-targeting T-cell engagers in follicular lymphoma and large B-cell lymphoma has further expanded the treatment options for patients with relapsed or […]

Treatment of Unresectable and Resectable Stage IV Colorectal Cancer

Abstract: Colorectal cancer is the third most commonly diagnosed cancer in the United States. Approximately 20% of patients have metastatic disease at diagnosis, and a proportion […]

Refining the Standard of Care in Immune Thrombotic Thrombocytopenic Purpura

Abstract: Acute immune thrombotic thrombocytopenic purpura (iTTP) is a medical emergency. In the setting of any thrombotic microangiopathy (TMA), blood should be drawn to measure ADAMTS13 […]

Management Options for Node-Positive Muscle-Invasive Bladder Cancer

Abstract: Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence […]

Clonal Hematopoiesis: Malignant Implications, Extrahematologic Manifestations, and Management

Abstract: As individuals age, their hematopoietic stem cells can sporadically acquire genetic mutations, known as clonal hematopoiesis. Although most of these genomic aberrations are of little […]

Uterine Serous Carcinoma and Uterine Carcinosarcoma: Molecular Features, Clinical Advances, and Emerging Therapies

Abstract: Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality. Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) make up a small but increasing […]

Antibody-Drug Conjugates in Advanced Lung Cancer: Is This a New Frontier?

Abstract: Over the past decade, the lung cancer landscape has been dominated by targeted and immunotherapeutic approaches that have drastically shifted treatment paradigms for patients with […]

Redefining the Standard of Care for Low-Grade Serous Ovarian Cancer

Abstract: Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted […]

Immune Checkpoint Inhibitor Therapy in Locally Advanced MSI GI Malignancies

Abstract: Locally advanced gastrointestinal (GI) malignancies have conventionally been treated in a multimodal fashion that combines (neo)adjuvant chemotherapy with or without radiation and definitive surgical resection. […]

Increasing Inclusion and Equity for Black Women in Breast Cancer Clinical Trials

Abstract: Black women diagnosed with breast cancer experience a disproportionately high mortality rate. The disparity in outcomes between Black and White women is multifactorial, with a […]

The Role of Noncovalent BTK Inhibitors in the Era of Covalent BTK Inhibitors

Abstract: Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some […]

Immunotherapy in the Treatment of Advanced or Recurrent Endometrial Cancer

Abstract: The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical […]

Management of KRAS-Mutated Non–Small Cell Lung Cancer

Abstract: Kirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non–small cell lung cancer (NSCLC), where mutations are present […]

Recombinant Interferon Alfa in BCR/ABL-Negative Chronic Myeloproliferative Neoplasms

Abstract: The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals […]

Evolving Applications of Liquid Biopsies in Gastrointestinal Cancers

Abstract: Liquid biopsy is a test that allows for the diagnosis and analysis of cancer by sampling cancer cells or byproducts present in biological fluids such […]

Risk Factors for Disease Progression and Treatment Goals in Polycythemia Vera

Abstract: Polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm characterized by the clonal proliferation of hematopoietic cells, leading to the overproduction of erythrocytes and the elaboration […]

Addressing Unmet Need in the Management of Patients With ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer: Clinician’s Perspective

Abstract: Approximately 70% of breast tumors are ER+ and HER2–. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the […]

Novel Combination Approaches to Locoregional and Systemic Therapy in the Management of Primary and Metastatic Liver Tumors

Abstract: Several pathways and mutations must develop or be in place for the onset of cancer. Therefore, therapies should ideally target as many of these pathways […]

Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer

Abstract: Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than […]

Surgical Resection Criteria and Neoadjuvant Therapies for Intrahepatic Cholangiocarcinoma

Abstract: The staging of intrahepatic cholangiocarcinoma (ICC) is complex, and there is no consensus among international cancer groups on how to most appropriately select candidates with […]